Fig. 3

# SDS-PAGE Analysis of 2H7 scFvIgG1 (SSS-S)H WCH2 WCH3 Protein.




Fig. 4A


Complement Mediated B Cell Killing After Binding of CD20-targeted 2H7 scFvIgG1 (SSS-S)H WCH2 WCH3:

2H7scFv-Ig Concentration		RAMOS cells/total cells		AB ve cells/total cells
20 μg/ml + complement	-	0.16	-	0.07
5 μg/ml + complement	-	0.2	-	N.D.
1.25 μg/ml + complement	-	0.32	-	0.1
Complement alone	-	0.98	-	0.94

<sup>\*</sup>Viability was determined by trypan blue exclusion and is tabulated as the fraction of viable cells out of the total number of cells counted.

Fig. 4B

Antibody-dependent cellular cytotoxicity (ADCC) mediated by 2H7scFv-IgG1 (SSS-S)H WCH2 WCH3:



<sup>\*\*</sup>N.D. (not determined).

PCT/US2003/041600

Fig. 5

Effects of Crosslinking of CD20 and CD40 Cell Surface Receptors on B Cell Proliferation:





Fig. 6



PCT/US2003/041600

#### Fig. 7A

2H7-CD154 L2 cDNA and predicted amino acid sequence: HindIII NCOI 2H7 V1 Leader Peptide → M D F Q V Q I F S F L L I S A S AAGCTTGCCG CC ATGGATTT TCAAGTGCAG ATTTTCAGCT TCCTGCTAAT CAGTGCTTCA  $2H7 V_L \rightarrow$ VIIA RGQ IVL ŠQSP AIL SAS GTCATAATTG CCAGAGGACA AATTGTTCTC TCCCAGTCTC CAGCAATCCT GTCTGCATCT 61 PGEKVTM TCR ASSS VSY M H W 121 CCAGGGGAGA AGGTCACAAT GACTTGCAGG GCCAGCTCAA GTGTAAGTTA CATGCACTGG BamHI Y Q Q K P G S S P K P W I Y A P S N L A 181 TACCAGCAGA AGCCAGGATC CTCCCCCAAA CCCTGGATTT ATGCCCCATC CAACCTGGCT SGVP ARF SGS GS GT SYS LTI 241 TCTGGAGTCC CTGCTCGCTT CAGTGGCAGT GGGTCTGGGA CCTCTTACTC TCTCACAATC SRVE A E D A A T Y Y C Q Q W S F N P AGCAGAGTGG AGGCTGAAGA TGCTGCCACT TATTACTGCC AGCAGTGGAG TTTTAACCCA 301 (Gly,Ser), Linker → PTFG AGT KLE LKGG GGS GG 361 CCCACGTTCG GTGCTGGGAC CAAGCTGGAG CTGAAAGGTG GCGGTGGCTC GGGCGGTGGT 2H7 V<sub>H</sub> → G S G G G S S O A Y L O O SGAELV 421 GGATCTGGAG GAGGTGGGAG CTCTCAGGCT TATCTACAGC AGTCTGGGGC TGAGCTGGTG R P G A S V K M S C K A S G Y T F T S Y 481 AGGCCTGGGG CCTCAGTGAA GATGTCCTGC AAGGCTTCTG GCTACACATT TACCAGTTAC NMHW VKO TPROGLE WIG AIY AATATGCACT GGGTAAAGCA GACACCTAGA CAGGGCCTGG AATGGATTGG AGCTATTTAT 541 F G N G D T S Y N O K F K G K A T L T V 601 CCAGGAAATG GTGATACTTC CTACAATCAG AAGTTCAAGG GCAAGGCCAC ACTGACTGTA DKSSSTAYMQLSSLTSEDSA 661 GACAAATCCT CCAGCACAGC CTACATGCAG CTCAGCAGCC TGACATCTGA AGACTCTGCG VYFC ARV VYY SNSY WYF DVW 721 GTCTATTCT GTGCAAGAGT GGTGTACTAT AGTAACTCTT ACTGGTACTT CGATGTCTGG

## Fig. 7A (continued)

#### human CD154/amino acid 48→

																		site		
	G	T	G	T	T	v	т	ν	S	D	P	R	R	L	D	K	Ι	E	D	E
781	GGC	ACA	GGG7	CC	ACG	TC2	AC	CGTC	TCT	GAT	CCA	AGA	AGGT	T	GGAC	AAG.	ΑT	AGAA	GAT	GAA
	R	N	L	н	В	D	F	v	F	M	K	T	I	Q	R	С	N	T	G	E
841	AGG	AAT	CTTC	AT	GAA	GAT'	TТ	TGTA	TTC.	ATG	AAA	ACG	ATAC	A	GAGA	TGC	AA	CACA	GGA	GAP
	R	s	т.	S	L	L	N	C	В	E	I	K	s	0	F	Е	G	F	v	K
901																				
																			В	c11
	D	I	м	L	N	K	Е	E	T	K	K	Е	N	s	F	Е	М	Q	ĸ	G
961	GAT	בידה בידה	ATC	יייי	AAC	AAA	GA	GGAG	ACG	AAG	AAA	GAA	AAC	A G	CTTI	GAA	AΤ	GCAA	AAA	GG1
501																				
	Bc1	τ																		
	~~~																			
			N	ъ	0	т	Δ	Δ	н	v	т	s	R	А	S	S	K	T	T	s
L021	CAM	~~	יים מיי	~~~	א גייני מגייני	V dad	cc.	cccs	CAT	GT/C	בידב	AGT.	GAG	າ ເ	CAGO	ים מי	ΔA	AACA	ACA	יייעד
	Ont	0.00					-													
	17	т.	0	w	7		v	c	v	v	m.	м	q	N.	N	τ.	v	т	τ.	E
1081																		AACC		
LUGI	GIG	LIM	CAG	1 60	JGC I	GAA	-un	AGG	iino											
	NT.	0	v	0	т.	m	17	v	ъ	0	G	т.	v	v	т	v	Δ	Q	v	m
1141	2.20	~~		~ ~	TOMO	12 CC	Om.	מאא	1202	C27	CCA	רידור	ጥልጥ	m²	ייית ביידי.	יתחי	יכר	CCA	AGTIC	ממי
TTAT	MAI	GGG	nnn	C A	3010	ncc	.G.	*****	4101		001									
						u i	nd.	III												
	100	~	e	M	D	12	Δ	s	s	0	A	P	F	I	A	s	L	С	L	ĸ
1201	mma	man	nmaa	2 7	nece	מממי	ar.	שתכי	ים מב	~× ชชช	CCT	······	արտ	Σ-1	PAGC	'AGC	יייי	CTGC	CTA	AA
1201	110	.10.		n n		, CJ		,,,,,,												
			_	n	173	-	ъ	-	r.	τ.	D		2	M	m	н	S	s	А	K
1261	maa	100	100	n	v mmc	7070	``	ית מי	ייייייי	CUTC	ACI	AGC1	איניי	Δ :	ስጥአ <i>ር</i> ሳ	יראר	'AG	TOTAL	rare	'AA
1201	100	.دد	1001	A G	MI-IC	June	MG	MAL	. 1 11	CIC	AGI	100		•••			,,,,			
	-	~		_	_		-	**			0	7.7	v	v	т.	^	ъ	G	Δ	c
1321	000	-m-c	2000		2027	, mar	ת בר	me A	ummv LL	3003	GG	CTI	nunu -	ຕິ	יתייים	יגיחים	م. م	AGG!	TGCT	րդոր
1321	CCI	TG	-666	CA	ACAN	1100	-MI	ICA		JUGE	. GG	1011	11 4 4		m11.4	JOIL		1100		
													Ncc	т						
													-~~							
		173	**	NT	**	m	ь	. 13	e	0	17					G	F	т	g	Б
1381	om.	r mm	v	, M	mam.	02 Q1	ייי	maa	220	אריי זמיייי	. cm	ava	ייי	ຕີ	acae	TCC	ייייי	י מאמ	CTC(	orpor -
1381	GTC	3T.T.	TGTC	A A	161	GAC.	IGA	. ICC	MMG	Chr	. 61	ono.	JUN 3		JUNG	100			010	
					-	har			-	haT										
						hoI														
	٠ _	_				-				n										
1441	G	L	Li m	K	L	15 TO 20		*	5	Z Z	77									
1441	G	GCT	TAC	ľCA	AAC'	TCG	AGI	G AI	WAT	CIA	311									

PCT/US2003/041600

## Fig. 7B.

2H7scFv-CD154 S4 cDNA and predicted amino acid sequence:


	HindIII NcoI
1	M D F Q V Q I F S F L L I S A S AAGCTTGCCG CC ATGGATTT TCAAGTGCAG ATTTTCAGCT TCCTGCTAAT CAGTGCTCA
	2H7 V <sub>L</sub> →
61	V I I A R G Q I V L S Q S P A I L S A S GTCATAATTG CCAGAGACA AATTGTTCTC TCCCAGTCTC CAGCAATCCT GTCTGCATCT
121	P G E K V T M T C R A S S S V S Y M H W CCAGGGGGA AGGTCACAAT GACTTGCAGG GCCAGCTCAA GTGTAAGTTA CATGCACTGG
	BamHI
181	Y Q Q K P G S S P K P W I Y A P S N L A TACCAGCAGA AGCCAGGATC CTCCCCCAAA CCCTGGATTT ATGCCCCATC CAACCTGGCT
	S G V P A R F S G S G S G T S Y S L T I
241	TCTGGAGTCC CTGCTCGCTT CAGTGGCAGT GGGTCTGGGA CCTCTTACTC TCTCACAATC
301	S R V E A E D A A T Y Y C Q Q W S F N P AGCAGAGTGG AGGCTGAAGA TGCTGCCACT TATTACTGCC AGCAGTGGAG TTTTAACCCA
	(Gly₂Ser)₃ Linker →
361	PTFGAGTKLELKGGGGGGGGGGGGCGGGGGCGCGGGGGGGGGGGGGG
	2H7 V <sub>H</sub> →
421	G S G G G G S S Q A Y L Q Q S G A E L V GGATCTGGAG GAGGTGGGAG CTCTCAGGCT TATCTACAGC AGTCTGGGGC TGAGCTGGTG
	RPGASVK MSC KASG YTF TSY
481	AGGCCTGGGG CCTCAGTGAA GATGTCCTGC AAGGCTTCTG GCTACACATT TACCAGTTAC
541	N M H W V K Q T P R Q G L E W I G A I Y AATATGCACT GGGTAAAGCA GACACCTAGA CAGGGCCTGG AATGGATTGG AGCTATTTAT
601	F G N G D T S Y N Q K F K G K A T L T V CCAGGAAATG GTGATACTTC CTACAATCAG AAGTTCAAGG GCAAGGCCAC ACTGACTGTA
661	D K S S S T A Y M Q L S S L T S E D S A GACARATCCT CCAGCACAGC CTACATGCAG CTCAGCAGCC TGACATCTGA AGACTCTGCG
721	V Y F C A R V V Y Y S N S Y W Y F D V W GTCTATTICT GTGCAAGAGT GGTGTACTAT AGTAACTCIT ACTGGTACTT CGATGTCTG

PCT/US2003/041600

	Fig. 7B						
	human CD154/amino acid 108 →						
	Bcl/Bam hybrid site						
	BclI						
781	G T G T T V T V S D P E N S F E M Q K G GGCACAGGGA CCACGGTCAC CGTCTCTGAT CCAGAAAACA GCTTTGAAAT GCAAAAAGGT						
	BelI						
841	D Q N P Q I A A H V I S E A S S K T T S GATCAGAATC CTCAAATTGC GGCACATGTC ATAAGTGAGG CCAGCAGTAA AACAACATCT						
901	V L Q W A E K G Y Y T M S N N L V T L E GTGTTACAGT GGGCTGAAAA AGGATACTAC ACCATGAGCA ACAACTTGGT AACCCTGGAA						
961	N G K Q L T V K R Q G L Y Y I Y A Q V T AATGGGAAAC AGCTGACCGT TAAAAGACAA GGACTCTATT ATATCTATGC CCAAGTCACC						
	HindIII						
	FCSN REASSQ APFIASL CLK						
1021	TTCTGTTCCA ATCGGGAAGC TTCGAGTCAA GCTCCATTTA TAGCCAGCCT CTGCCTAAAG						
1081	S P G R F E R I L L R A A N T H S S A K						
1001	TCCCCCGGTA GATTCGAGAG AATCTTACTC AGAGCTGCAA ATACCCACAG TTCCGCCAAA						
1141	P C G Q Q S I H L G G V F E L Q P G A S CCTTGCGGGC AACAATCCAT TCACTTGGGA GGAGTATTTG AATTGCAACC AGGTGCTTCG						
	Ncol						
	V F V N V T D P S Q V S H G T G F T S F						
1201	GTGTTTGTCA ATGTGACTGA TCCAAGCCAA GTGAGCCATG GCACTGGCTT CACGTCCTTT						
	XhoI XbaI						
	G L L K L E * * S R						
1261	GGCTTACTCA AACTCGAGTG ATAATCTAGA						

PCT/US2003/041600

Fig. 8
Simultaneous Binding of 2H7scFv-CD154
Fusion Proteins to CD20 and CD40



CD20 CHO cell targets + (control or fusion protein) + Biotin-CD40Ig + PE-SA

PCT/US2003/041600

Fig. 9

Induction of Apoptosis Measured by Binding of Annexin V after incubation with 2H7scFv-CD154





Fig. 10

#### Proliferation of T51 B Cell Line After Incubation with 2H7 scFv-CD154 S4 or 2H7 scFv-CD154 L2 Constructs



Fusion Protein

PCT/US2003/041600

Fig. 11
Schematic Representation of 2H7 scFvIg Constructs

2H7 scFvlgG (SSS-S)H WCH2 WCH3 OR 2H7 scFvlgG1 (SSS-S)H P238SCH2 WCH3: 2H7 scFv Human IgG CH2-CH3 Н СНЗ CH2 СНЗ K320 E318 "N297/"N23370 E318/E [asp-gly<sub>3</sub>-ser-{gly<sub>4</sub>ser}<sub>2</sub>] C229→S C226→S C220→S peptide linker 2H7 scFv-lgAH G1-WCH2 WCH3: 2H7 scFv Human IgG1 CH2-CH3 hulgAhinge СНЗ CH2 СНЗ hulgAhinge PASPSPTPPTSPSPTPPTSPVPQD =Complement Fixation

hay, franco pares dons esti

WO 2005/017148 PCT/US2003/041600

#### Fig. 12




Figure 12: SDS-PAGR Analysis of CytoxB Derivatives. Purified fusion protein derivatives of CytoxB-scFvIg molecules and Rituximab were resuspended SDS sample buffer, boiled, loaded onto 10% Novex Tris-Bis gels (invitrogen, San Dlego, CA) and subjected to nonreducing (left panel) or reducing (right panel) SDS-PAGE electrophoresis at 175 volts. Two different molecular weight markers, Blorda prestained markers, and Novex Multimark molecular weight markers were also loaded onto each gel and the approximate size in kDa of each marker band is indicated along each side of the photographed gels. Gels were stained in Comassis Blue stain and photographed with a SONY Mavica Digital camera. The mutant hinge forms of 2H7 scFv[9G] migrate at approximately 70 kDa under both nonreducing and reducing conditions, indicating that these molecules are monomeric rather than dimeric in structure. The IgA hinge form of 2H7scFvIg migrates at approximately 75 kDa under reducing conditions, but migrates predominately as a dimer of 14d kDa with a fraction of the protein migrating at 75 kDa under nonreducing conditions. Under nonreducing conditions, rituximab migrates as a diffuse band of between 150 and 200 kDa. The heavy and light chains resolve into separate bands of between 150 and 200 kDa. The heavy and light chains resolve into separate bands of septonimately 23 and 50 kDa when rituximab is reduced and subjected to SDs-8-AGE.

Fig. 13

### ADCC Activity of CytoxB (2H7 scFvIg) Constructs.




Figure 13: ADCC Activity of CytoxB Derivatives Compared to Rituximab. ADCC activity of CytoxB Derivatives or Rituximab was measured in vitro against BJAB B lymphoma cell line as target and using fresh human PBMC as effector cells. Effector to target ratios were varied as follows: 70:1, 35:1, and 18:1, with the number of BJAB cells per well remaining constant but varying the number of PBMC. Bjab cells were labeled for 2 hours with <sup>51</sup>Cr and aliquoted at a cell density of 5x10<sup>4</sup> cells/well to each well of flatbottom 96 well plates. Purified fusion proteins or rituximab were added at a concentration of 10 mg/ml, and PBMC were added at 9x10<sup>5</sup> cells /well (18:1), 1.8x10<sup>6</sup> cells/well (35:1), or 3.6x10<sup>6</sup> cells/well (70:1), in a final volume of 200 µL. Spontaneous release was measured without addition of PBMC or pision protein, and maximal release was measured by the addition of detergent (1% NP-40) to the appropriate wells. Reactions were incubated for 4 hours, and 100 ml culture supernatant harvested to a Lumaplate (Packard Instruments) and allowed to dry overnight prior to counting cpm released on a Packard Top Count NXT Microplate Scintillation Counter.

PCT/US2003/041600

Fig. 14

#### CDC of Cytox B (2H7 scFvIg) Constructs





Figure 14: Complement Dependent Cytoxicity (CDC) Activity of CytoxB Derivatives Compared to Rituximab. 2H7 scFvIgG1 (SSS-S)H WCH2 WCH3, 2H7 scFvIgG1 (SSS-S)H WCH2 WCH3, and 2H7 scFv IgA WH IgG1 WCH2 WCH3 derivatives and Rituximab were compared for their ability to mediate complement dependent cytoxicity. Rabbit complement (Pel-Freez) was diluted 1:10 and added to B1AB cells along with dilutions of each antibody derivative (20 μg/ml, 10 μg/ml, and 5 μg/ml). Controls were also included without addition of complement (C') or scFv derivative. Reactions were allowed to continue for 1 hour, and cells from each well were then stained with trypan blue and the cell viability counted using a hemacytometer. Data is graphed as % of dead cells/total cells counted for each condition assayed.

Fig. 15

#### 2H7 (anti-CD20) scFv IgG1 (SSS-S)H WCH2 WCH3 In Vivo Half Life



#### Macague A99314

	Day	Binding intensity (LFE) @1:50 dilution of serum	estimated concentration (μg/ml)
injection #1	-7	0.213	<0.1
injection #1	-0	0.227	<0.1
	1	7.79	25.1
	3	5.51	15.6
Injection #2	7	3.37	9.4
	8	11.33	41.7
	10	5.45	15.4
	14	0.27	<0.1


#### Macaque F98081

	Day	Binding intensity (LFE)  @ 1:50 dilution of serum	estimated concentration (µg/ml)
	-7	0.208	<0.1
Injection #1	0	0.219	<0.1
	1	6.73	21.9
	3	6.14	19.3
Injection #2	7	3.04	8.7
-	8	9.83	33.8
	10	4.77	14.4
	14	0.231	<0.1

PCT/US2003/041600

Fig. 16

B Cell Depletion in macaques mediated by Cytox B20 (2H7 scFv IgG1 (SSS-S)H WCH2 WCH3) Construct




- · CytoxB20 injections of 6mg/kg yields 3 week B-cell depletion
- · 3-4 day half-life in vivo
- CD20 saturation in lymph node B-cells at d14
- · No first dose effects
- · No anti-chimeric antibody development

PCT/US2003/041600

Fig. 17

### Production Levels of HD37 scFvIg Constructs by CHO Cell Lines



Clone/Isolate	Mean LF	E at 1:100	Estimated Concentration
Bulk HD37 scFv			
IgA WH IgG1 WCH2 \	NCH3	11.2	> 60 ug/ml
1B2		10.4	>50 ug/ml
6C5		10.5	>50 ug/ml
4B1		8.6	>40 ug/ml
Bulk HD37 scFv			
IgG1 (SSS-S)H WCH	2 WCH3	10.9	> 50 ug/ml
2G8		10.6	> 50 ug/ml
3F3		8.3	>40 ug/ml
3D9		11.1	> 60 ug/ml

PCT/US2003/041600

Fig. 18

#### Production of L6 scFvIg constructs by CHO Cells






Fig. 19


## ADCC Activity of 2H7 scFvIg, G28-1 scFvIg, and HD37 scFvIg Constructs

ADCC Activity of scFvs Targeted to B Cell Antigens



B. G28-1 (anti-CD37) scFv constructs






PCT/US2003/041600

Fig. 20

### ADCC Activity of L6 scFvIg Constructs


#### ADCC Activity of L6scFvlg Constructs with 2981 Targets



PCT/US2003/041600

Fig. 21


## SDS-PAGE Analysis of L6 and 2H7 scFvIg Fusion Proteins.



PCT/US2003/041600

Fig. 22

SDS-PAGE Analysis of G28-1 and HD37 scFvIg Constructs.



TITALOT

PCT/US2003/041600

Fig. 23

Sequence alignment of human and llama Fc regions.

		HINGE	CH2 <del>→</del>
ma ma	IgG2: IgG1:	DQEPKTPKPQPQPQPQPNPTTESKCPKC EPHGGCTCPQC	PAPELLOGPSVFLFPPKDVLMISRTPEVTCVVVDVSHEDPEVKFNWVVDO PAPELLOGPSVFIFPPKKDVLSISGREPVTCVVVDVQQDPENFSHWYIDD PAPELLOGPSVFUPPEKBVDVLSISGRPEVTCVVVDVVGKEDPEVHFNWYIDD POPELLOGPTVFIFPPKAKDVLSITKREPVTCLWWTWKKILNSSSSWSVDD

CITA \

VENDMAKTERESOVNSTYKVUSULTVALIGOMAKKEYKCKVSINKALPAP IEKET EKKAGOGERSOVYLTU PERDELTKINGUSULT TABENAMTRIPESOONSTYKVUSULTUIGIOMAKKARSEKCUNINKALPAP IEKET ISKAGOGERSOVYLTA BIRESLADDVSVT VENERAMTRIPESOONSTYKVUSULTIOIGOMAKARSEKCUNINKALPAP IERET ISKAGOGERSOVYLTA BIRESLADDVSVT VENERAMTRIPESOONSTYKVUSULTIOIGOMAKARSEKCUNINKALPAP IERET ISKAGOGERSOVYLTA BIRESLADDVSVT VENERAMTRIPESOONSTYKVUSULTIOIGOMAKARSEKCUNINKALPAP IERET ISKAGOGERSOVYLTA BIRESLADDVSVT

CLYMSFFFBCIAVENERNOPEN—NYKTFFYULBDSFFFLYSKLYUNKSKYCCHYFGCSYMHEALHNITYCKSLSLSFKKLSENFYCCUMERALHNITYCKSLSLSFKKLYUNKSKYCCHYFGCSTWIFCAHNNITYCKSLSLSFKKLSKYKKLYUNKSFFFBCIAVENFYCKSTYLSFKKLYUNKSFYLSFKKLYKKYKKLYUNKSFTLYSKKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYKLYUNKSFTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTALSKYTA

PCT/US2003/041600

Fig. 24





Fig. 25



PCT/US2003/041600

Fig. 26

2H7 scFvIg Llama Tails binding Assay with CD20 CHO Cells




Fig. 27






Fig. 28

#### ADCC Assay with BJAB Cells And Llama PBMC Effectors




PCT/US2003/041600

Fig. 29



PCT/US2003/041600

Fig. 30



PCT/US2003/041600

Fig. 31

## Ig Constructs and Nomenclature:

Name Identifier	Hinge Sequence	CH2 Sequence	CH3 Sequence
hIgG1 (CCC-P)H WCH2 WCH3	IgG1 WT Hinge (CCC-P)	Wild Type CH2	Wild Type CH3
hIgG1 (SSS-S)H WCH2 WCH3	IgG1 Mutant Hinge (SSS-S)	Wild type CH2 (IgG1)	Wild type CH3 (IgG1)
VH L11S hIgG1 (SSS-S)H WCH2 WCH3	IgG1 Mutant Hinge (SSS-S)	Wild type CH2 (IgG1)	Wild type CH3 (IgG1)
IgG1 (SSC-S)H WCH2 WCH3	IgG1 Mutant Hinge (SSC-S)	Wild type CH2 (IgG1)	Wild type CH3 (IgG1)
IgG1 (SCS-S)H WCH2 WCH3	IgG1 Mutant Hinge (SCS-S)	Wild type CH2 (IgG1)	Wild type CH3 (IgG1)
IgG1 (CSS-S)H WCH2 WCH3	IgG1 Mutant Hinge (CSS-S)	Wild type CH2 (IgG1)	Wild type CH3 (IgG1)
IgG1 (SSS-S)H P238S CH2 WCH3	IgG1 Mutant Hinge (SSS-S)	Mutant CH2 (IgG1) Pro→Ser 238	Wild type CH3 (IgG1)
IgA WH hIgG1 WCH2 WCH3	IgA Hinge	Wild type CH2 (IgG1)	Wild type CH3 (IgG1)
IgA WH IgA WCH2 WCH3	IgA Hinge	Wild type CH2 (IgA)	Wild type CH3 (IgA)
IgA WH IgA WCH2 T4CH3	IgA Hinge	Wild type CH2 (IgA)	Truncated CH3 (IgA) Missing 4 aa at COOH

PCT/US2003/041600

Fig. 32




Fig. 33





Fig. 34

## Binding of 2H7 scFvIg Constructs with Alternative Tails to CD20 CHO Cells



PCT/US2003/041600

Fig. 35

Immunoblot Analysis of protein immunoprecipitates from COS transfections of 2H7 scFvIg Constructs





Fig. 36


Binding to CD20 CHO cells by constructs that link anti-CD20 scFv to IgA Fc Domains



PCT/US2003/041600

Fig. 37


# Titration of CD20 specific scFvIg Constructs for ADCC Activity Using Whole Blood Effectors



PCT/US2003/041600

Fig. 38


## ADCC Assay of anti-CD20 constructs with alternative tails (Whole Blood Effectors / BJAB Targets




PCT/US2003/041600

Fig. 39

ADCC Assay of Anti-CD20 scFvIg Constructs Using Different Effector Populations Against BJAB Targets







WO 2005/017148 PCT/US2003/041600

Fig. 40

Immunoblot of 2H7 scFv Ig constructs from COS Transfections (1  $\mu$ l/well) compared to a Concentration Standard




Figures 41A, 41B and 41C



PCT/US2003/041600


Fig. 42



PCT/US2003/041600

Fig. 43


## Mixtures of K1735-WT and K1735-1D8 transfected tumor lines inhibit tumor outgrowth in C3H mice



PCT/US2003/041600

Fig. 44

Expression of anti-mouse CD137 (1D8) scFv-hIgG1 (SSS-S)H P238SCH2 WCH3
On the surface of panned Ag104-1D8 Transfected Tumor Cells




Brightness

WO 2005/017148 PCT/US2003/041600

Fig. 45


### Coomassie Stained SDS-PAGE Gel of 2H7 scFv Ig



PCT/US2003/041600

Fig. 46

# ADCC mediated by 2H7 scFvIg Constructs by human PBMC effector cells against Bjab targets



- 2H7 scFv hlgG1(SSS-S)H P238SCH2 WCH3
- ▲ 2H7 scFv hlgA WH lgG1 WCH2 WCH3
- 2H7 scFv hlgG1 (SSS-S)H WCH2 WCH3
- RITUXIMAB
- \* CELLS ALONE (W/O AB)


PCT/US2003/041600

Fig. 47

Cell surface expression of anti-human CD3 G19-4 scFv hIgG1 (SSS-S)H P238SCH2 WCH3-hCD80TM/CT on Reh and T51 Cells.

Reh anti-CD3 (G19-4) scFv hIgG1 (SSS-S)H

P238SCH2 WCH3-hCD80TM/CT



T51 G19-4 scFv hlgG1 (SSS-S)H P238SCH2 WCH3-hCD80TM/CT:






Figure 48.

Targeting of Cytotoxicity to Transfected Cell Lines by Surface expression of CD3 scFvIg Cytotxic activity of resting PBMC towards transfected Reh cells




Cytotoxic activity of resting PBMC towards transfected T51 lymphoblastoid cells



PCT/US2003/041600

Fig. 49

Binding of 5B9, a mouse anti-human CD137 scFv hIgG1 (SSS-S)H WCH2WCH3 to stimulated human PBMC




- 5B9 Hybridoma supernatant + GAM IgG FITC
- 5B9scFv hIgG1 (SSS-S)H WCH2 WCH3
  COS supernatant +GAH IgG FITC

WO 2005/017148 PCT/US2003/041600

Fig. 50

## Effect of $V_H L11S$ Mutation on CytoxB20 2H7 scFv hlgG1 (SSS-S)H WCH2 WCH3 Protein Expression

50A. Standard Curve: 2H7VH-L11S-IgG1 (SSS-S)H WCH2 WCH3




50B. CHO supernatant Brightness and Estimation of Protein concentrations from Standard Curve:

	CHO clone name					
	4F2	4F5	3E5	6B11A	2B8A	
Mean LFE	Ξ					
1/100	71.7	40.6	31.5	99.7	101.5	
1/500	27.1	12.4	11.2	40.8	43	
approx conc. μg/ml	600	225	125	1000	1250	

Fig. 51


### Production Levels of 2H7scFv VH L11S hIgG1 (SSS-S)H WCH2 WCH3 From CHO Clone Culture Supernatants



PCT/US2003/041600

Fig. 52

## Effect of VHL11S Mutation on G28-1 scFvIg Construct Protein Production from COS cells



PCT/IIS2003/041600

G28-1VHL11S

scFv hlgG1 (SSS-S)H

1 ul/well

Fig. 53

### Immunoblot of G28-1 scFvIg Constructs


Increased Protein Levels in COS supernatants transfected with G28-1scFv hlgG1 (SSS-S)H WCH2 WCH3 After Substitution of Leucine with Serine at position 11 of VH (VHL11S)

Fig. 53A. Fig. 53B. Purified G28-1 Purified G28-1 G28-1 scFv (11/6/01) (11/6/01) hlgG1 (SSS-S)H scFv hlgG1(SSS-S)H WCH2 WCH3 scFv lgG1 (SSS-S)H WCH2 WCH3 WCH2 WCH3 WCH2 WCH3 1 ul/well ABCDE

PCT/US2003/041600

Fig. 54


Binding of 2H7 scFvIg Constructs with Altered Hinges and CH3 domains to CD20 CHO Cells



PCT/US2003/041600

Fig. 55


#### ADCC Activity of 2H7 scFvlg constructs Against BJAB Targets and PBMC Effectors



PCT/US2003/041600

Fig. 56

# Complement Activity of 2H7 scFvIg Constructs With Ramos Target Cells




PCT/US2003/041600


Fig. 57

#### Binding of 2H7 scFvIg Derivatives to CD20CHO Cells


- A. No fusion protein
- B. 2H7 scFv hlgE CH2CH3CH4
- C. 2H7 scFv hlgA WH WCH2 WCH3
- D. 2H7 scFv hlgG1 (SSS-S)H WCH2 WCH3



#### FITC anti-hlgA



#### FITC anti-hlgE



## Fig. 58

Fig. 58A. 2H7 scFv VH L11S human IgE (WCH2 WCH3 WCH4) Binding to CD20 CHO at 30 ug/ml





Fig. 58B. ADCC Activity of 2H7 VHL11S IgE (WCH2 WCH3 WCH4)
Protein Fractions with PBMC Effectors and Bjab Targets



PCT/US2003/041600

Fig. 59

Binding Data for COS derived α-CD20 (2H7) scFv VHL11S mIg E (WCH2 WCH3 WCH4) and mIgA (WH WCH2 WCH3)Tailed Molecules




Fig. 60






Fig. 61



WO 2005/017148 PCT/US2003/041600


Fig. 62



PCT/US2003/041600


Fig. 63

Binding of Purified Proteins from COS Supernatants to CD20 CHO cells: Differential Effects of CH3 Mutations on Binding



PCT/US2003/041600


Fig. 64



PCT/US2003/041600

Fig. 65


Nonreducing SDS-PAGE on Protein A-Purified Lots of 2H7 scFv VHL11S hig Constructs (10 ug/lane)



PCT/US2003/041600

Fig. 66


#### Alterations in Human IgG Fc sequence that differentially change effector function efficiency



CDC residue ADCC

PCT/US2003/041600


## Figure 67.



PCT/US2003/041600

Fig. 68


CD16(ED) hIgG1(SSS-S)H P238S CH2 WCH3 high and low affinity alleles expressed as soluble molecules



PCT/US2003/041600

Fig. 69


Binding of soluble CD16-FITC high and low affinity fusion proteins to 2H7 scFv VHL11S higG1 (CSC-S)H WCH2WCH3 or (SSS-S)H (P238S)CH2WCH3 on CD20CHO Targets



WO 2005/017148 PCT/US2003/041600

Fig. 70

Binding of FITC Labeled, Recombinant Human CD16(ED) extracellular domain -Ig Fusion Protein to CytoxB Derivatives on CD20 CHO Cells



Expression of surface displayed SMIPs links modified cDNAs with the altered fusion proteins






Fig. 71

## CD37 mAbs and scFvIg Induce Apoptosis

	Bjab Staining	Annexin V Positive	
scFvig	No scFvlg	17.5	
	2H7 MH	27	
	G28-1 MH	30.6	
	G28-1 IgAH	28.9	
	HD37 MH	29.1	
	(2H7+G28-1)MH	41	
	(2H7+HD37) MH .	37.1	
	(G28-1+HD37) MH	35.3	
			plus GAM
	Ramos	AnnexinV Positive	AnnexinV positive
	cells alone	3	3.3
	2H7 Mab	1.4	3.1
	G28-1 Mab	18.3	8.7
	HD37 Mab	3.7	3.1
	G28-5	3.9	8.3
	2H7+G28-1	32.3	35.7
	2H7+HD37	5	10.5
	2H7+G28-5	5.7	19.4
	HD37+G28-1	26.9	50
	HD37+G28-5	8.2	18.4
	G28-1+G28-5	39.5	68.3



### Complement Dependent Cytotoxicity Mediated by CytoxB20G Derivatives




cells and only one reagent were also included. of 100 microliters for sixty minutes. Aliquots were stained with trypan blue (Invitrogen), and counted using a hemacytometer to determine the percentage of the cell population killed during treatment. Negative controls with increasing concentrations with 104 Bjab Target Cells and a 1:10 dilution of rabbit complement (PelFreez) in a volume Figure 76: CDC Activity of CytoxB20G SMIPS. CytoxB20G, CytoxB20GP238, or Rturximab were incubated at

ADCC Activity of CytoxB20G SMIPS

### % Specific Killing 8 25 Effector: Target Ratio 75 6 -x-Natural Killing --- RITUXIMAB — CytoxB20G CytoxB20G P238S Fig. 74


dry overnight prior to counting cpm released on a Packard Top Count NXT Microplate Scintillation Counter. incubated for 5 hours, and 100 µl culture supernatant harvested to a Lumaplate (Packard Instruments) and allowed to maximal release was measured by the addition of detergent (1% NP-40) to the appropriate wells. Reactions were omission of SMIP or MAb. Spontaneous release was measured without addition of PBMC or fusion protein, and 10° cells/well (100:1), in a final volume of 200 μl. Natural Killing was measured at each effector:target ratio by concentration of 10  $\mu$ g/ml, and PBMC were added at 1.25 x 10 $^{\circ}$  cells/well (25:1), 2.5 x 10 $^{\circ}$  cells/well (50:1), or 5 x cells/well to each well of flat-bottom 96 well plates. Purified fusion proteins or rituximab were added at a varying the number of PBMC. Bjab cells were labeled for 2 hours with 51Cr and aliquoted at a cell density of 5x104 ratios were varied as follows: 100:1, 50:1, and 25:1, with the number of BJAB cells per well remaining constant but vitro against BJAB B lymphoma cell line as target and using fresh human PBMC as effector cells. Effector to target Figure 77: ADCC Activity of CytoxB20G SMIPS. ADCC activity of CytoxB20G or Rituximab was measured in

# ылаing of soluble FITC-CD16 to CytoxB20G on CD20 CHO




analyzed using Expo analysis software and normalized fluorescence units graphed as a function of concentration washed and specific binding measured by flow cytometry using a Beckman-Coulter Epics C machine. Results ; washed in PBS/2% FBS and incubated with serial dilutions of 0.5 mg/ml FITC-CD16 for one hour on ice. Cells 1 saturating amounts of CytoxB20G or CytoxB20G P238S(10 ug/ml) for one hour on ice in PBS/2% FBS. Cells re 78: Binding of soluble FITC-CD16 to CytoxB20G on CD20 CHO cells. CD20 CHO cells (106) were incubated

### CytoxB20G and CytoxB20G P238S SMIPS bind to U937 Cells Expressing FcyRI High Affinity FcR




/zed using Expo analysis software, and fluorescence intensity graphed as a function of SMIP concentration expressing CD64 were incubated in PBS/2%FBS for one hour on ice with CytoxB20G orCytoxB20G P238S. Cells re 79: CytoxB20G SMIPs bind similarly to U937 cells expressing the high affinity FcR (Fc/RI, CD64). U937 cells Cells were washed and fluorescence analysed on a Beckman-Coulter EpicsC flow cytometer. Data was washed and incubated for one hour on ice with FITC-goat anti-human IgG1 (Fc specific) (Caltag ) at a final dilution



ttions. Data are plotted as the number of CD40 positive blood B cells tabulated in thousands of cells per FITC or PE conjugates of antibodies against CD40, CD19, CD20, IgG, CD3, CD8 were used in various n was estimated by performing CBC (complete blood counts) and two color flow cytometry analysis on monkey CytoxB20G or CytoxB20G P238S were administered to macaques by intravenous injection at 6 mg/kg, with er over time relative to the initial pre-injection time point level of B cells (maximum). neral blood. Blood samples were drawn from injected animals at days -7,0,1,3,7,8,10,14, 28, and 43. B cell isions given one week apart. The effect on circulating B cells was measured by detection of CD40 positive B cells

## Figure 81: SEC on CytoxB37G SMIPs containing SSS and SSC hinge Domains from Human IgG1




molecular weight standards are indicated below the tracing. The CytoxB37G (SSS)H SMIP size 5 µm. The flow rate was 1ml/min, in PBS, pH 7.2 running buffer. Migration rates of μg were subjected to HPLC over a Tosoh Biosep, Inc. TSK 3000 SWXL HPLC column, por indicated in blue, while the CytoxB37G (CSS)H is indicated in red. CHO culture supernatants by Protein A affinity chromatography. Purified aliquots of 10-25 Figure 81: SEC (Size Exclusion Chromatography) CytoxB37G SMIPs were purified from

ô

Ô





i and FITC goat anti-human IgG F(ab')2 (CalTag) at 1:100 each, on ice for 45 minutes. Samples were washed and tutes on ice in PBS/2%FBS. Samples were washed twice, and incubated with a mixture of FITC goat anti-human ified CytoxB37 (SSS)H G or CytoxB37 (SSC)H G SMIPS were incubated with 10° cells of each cell type for 60 ure 82: Binding of CytoxB37G SMIPS to B cell lymphoma cell lines. Serial dilutions of lyzed by flow cytometry using a FACsCalibur (Becton-Dickinson)






Figure 84: Thymidine Incorporation (Growth Inhibition) in Ramos Bcells after a 48 Hour Incubation with anti-CD37 SMIPS




rre 84: Ramos B cells were incubated with serial dilutions of purified CD37G SMIPS containing sasing protein concentration rporated versus protein concentration. Each SMIP show increasing inhibition of proliferation with ning on a TopCount NXT microplate (Packard) scintillation counter. Data are plotted as cpm g a Packard harvester, dried, and 25 μl Microscint scintillation fluid added to each well prior to 12 hours of a 48 hour incubation (0.75 µCi/well). Cells were harvested onto 96-well GFC plates te culture dishes (Costar) at 37°C, 5%CO<sub>2</sub> for 36 hours prior to pulsing with <sup>3</sup>H-thymidine for the 2r the IgG1 hinge identified as (SSS)H or (SSC)H. Cultures were incubated in 96 well flat bottom

ure 85:

The Induction of Apoptosis in Ramos B-cells after a 20 hour incubation with different combinations of CD20 and CD37 targeted SMIPS






87/88

WO 2005/01/14

Figure 87: ADCC Activity of CD37 SMIPs Against Ramos Targets



88/88

Scintillation Counter. and allowed to dry overnight prior to counting cpm released on a Packard Top Count NXT Microplate were incubated for 6 hours, and 100 ml culture supernatant harvested to a Lumaplate (Packard Instruments) by omission of SMIP. Spontaneous release was measured without addition of PBMC or fusion protein, and cells and resting human PBMCs at different effector:target ratios ranging from 0 to 100. All incubations were maximal release was measured by the addition of detergent (1% NP-40) to the appropriate wells. Reactions performed in triplicate at each effector:target ratio. Natural Killing was measured at each effector:target ratio Figure 87: CD37 SMIPS at 10 μg/ml were incubated in flat-bottom 96 well plates with 10<sup>4 51</sup>Cr-labeled Ramo:

### INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/41600

I A. CLA	SSIFICATION OF SUBJECT MATTER			
IPC(7)	: C12N 15/00; A61K 39/395; C07K 16/00			
US CL	: 530/387.3, 388.85, 391.3; 424/130.1; 536/2	3.4: 435/30	20.1.69.6	
According to	International Patent Classification (IPC) or to both	national cl	assification and IPC	
B. FIEI	DS SEARCHED		and II o	
Minimum de	ocumentation scarched (classification system followe	d become		
U.S. : 5	530/387.3, 388.85, 391.3; 424/130.1; 536/23.4; 435	/320.1, 69	.6	
Documentati	ion searched other than minimum documentation to t	he extent tl	nat such documents are included	in the fields searched
Electronic da Please See C	ata base consulted during the international search (na continuation Sheet	me of data	base and, where practicable, sea	rch terms used)
C. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where	opposation		
Y	HAYDEN et al. Single-chain mono- and bispecifi	appropriat	e, of the relevant passages	Relevant to claim No.
•	biological propriets and antimono and obspecti biological propriets and antimono activity from C Therapeutic Immunology, 1994, Vol. 94, pages 3-	OS cell tra	insient expression system	1-7, 20-28, 31-40, 53- 57, 59, 62-63, 65-75, 116-119, 129-137, 140- 150, 161-169, 171-181, 238, 240-243, 251-259, 261-267, 282-285, 287- 295, 399-411
Y	US 6,147,203 A (PASTAN et al.) 14 November 26 especially abstract, column5-6.	00 (14.11.2	000), see entire document,	1-7, 20-28, 31-40, 53- 57, 59, 62-63, 65-75, 116-119, 129-137, 140- 150, 161-169, 171-181, 238, 240-243, 251-259, 261-267, 282-285, 287- 295, 399-411
	documents are listed in the continuation of Box C.		See patent family annex.	
"A" document	ecial categories of cited documents: defining the general state of the art which is not considered to be ar relevance	"T"	later document published after the inte date and not in conflict with the applic principle or theory underlying the inve	
	lication or patent published on or after the international filling date	*X*	document of particular relevance; the considered novel or cannot be consider when the document is taken alone	claimed invention cannot be red to involve an inventive step
establish th specified)	which may throw doubts on priority claim(s) or which is cited to ne publication date of another citation or other special reason (as	"Y"	document of particular relevance; the considered to involve an inventive sur-	
	referring to an oral disclosure, use, exhibition or other means		combined with one or more other such being obvious to a person skilled in the	documents, such combination
priority dat		*&*	document member of the same patent f	amily
	tual completion of the international search	Date of	mailing of the international searc	h report
	04 (29.10.2004) ling address of the ISA/US		UZ NOV 2004	
	Stop PCT, Attn: ISA/US	Authori	ed officer R MICE	No fr
Com	missioner for Patents	Lighty I	Wile BMG	( /)
	Box 1450	1 7		$\nu_{\scriptscriptstyle{-}}$
Alexa Facsimile No.	andria, Virginia 22313-1450 (703) 305-3230	Telephor	10 No. 571-272-	1600
	(705) 505-5250 (210 (second sheet) (July 1998)			
orm PC1/ISA/	210 (second sheet) (Inly 1998)			

### INTERNATIONAL SEARCH REPORT

ı	PCT/US03/41600	
ı		

tegory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	US 6,074,644 A (PASTAN et al.) 13 June 2000 (13.06.2000), see entire document, especially column 20.	26, 28, 32, 135, 13 142, 257, 259, 26
Y	US 5,677,425 A (BODMER et al.) 14 October 1997 (14.10.1997), see entire document, especially abstract, column 3-4.	65-75, 116, 172-18 288-295
Y	US 6,482,919 B2 (LEDBETTER et al.) 19 November 2002 (19.11.2002), see entire document.	180

Form PCT/ISA/210 (second sheet) (July 1998)

Continuation of B. FIELDS SEARCHED Item 3:  CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, sety, hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, IgG1, IgA, IgE, disulfide arbitred, constnar region.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, al
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, al
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, al
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, al
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
CAPLUS, MEDLINE, WEST, BIOSIS Search terms: inventor name, scfv. hinge, cysteine, fusion protein, CD19, CD3, deleted hinge, altered hinge, altered hinge, altered hinge.
Search terms: inventor name, sefy, hinge, exsteine, fusion protein CD19 CD3 deleted hinge altered hinge 1-01 T-1 T-2 IIII.
·
8